Artiva Biotherapeutics, Inc. - Common Stock (ARTV)

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of $11.52 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 2,170,138 shares of common stock at a purchase price of $11.5199 per share, which equals the offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. All the shares of common stock and pre-funded warrants in the offering are being sold by Artiva.

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis.

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Myseum, Inc. (Nasdaq: MYSE) a leader in digital privacy and next-generation social media technology, today announced the successful completion of the sale of its approximately 35% minority ownership interest in RPM Interactive, Inc. (“RPM”), following Avalon GloboCare Corp.’s (Nasdaq: ALBT ) agreement to acquire 100% of RPM .

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff

Over 100 patients treated with AlloNK across autoimmune and oncology indications

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --  Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences:

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Shares of Artiva Biotherapeutics, Inc. are rising Friday after the San Diego-based biotech company shared a milestone regulatory update.

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.